US4792569A
(en)
*
|
1987-08-27 |
1988-12-20 |
Mcneilab, Inc. |
Anticonvulsant phenethyl sulfamates
|
US5273993A
(en)
*
|
1989-06-12 |
1993-12-28 |
A. H. Robins Company, Incorporated |
Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
|
US5194446A
(en)
*
|
1989-06-12 |
1993-03-16 |
A. H. Robins Company, Incorporated |
Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
|
PT94305B
(pt)
*
|
1989-06-12 |
1997-02-28 |
Robins Co Inc A H |
Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
|
US5192785A
(en)
*
|
1989-09-03 |
1993-03-09 |
A. H. Robins Company, Incorporated |
Sulfamates as antiglaucoma agents
|
US6476011B1
(en)
|
1991-08-28 |
2002-11-05 |
Sterix Limited |
Methods for introducing an estrogenic compound
|
US6011024A
(en)
|
1991-08-28 |
2000-01-04 |
Imperial College Of Science Technology & Medicine |
Steroid sulphatase inhibitors
|
US6903084B2
(en)
|
1991-08-29 |
2005-06-07 |
Sterix Limited |
Steroid sulphatase inhibitors
|
AU651244B2
(en)
*
|
1991-09-19 |
1994-07-14 |
Mcneilab, Inc. |
Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
|
US5242942A
(en)
*
|
1992-04-28 |
1993-09-07 |
Mcneilab, Inc. |
Anticonvulsant fructopyranose cyclic sulfites and sulfates
|
US5258402A
(en)
*
|
1992-06-11 |
1993-11-02 |
Mcneil-Ppc, Inc. |
Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
|
US5384327A
(en)
*
|
1992-12-22 |
1995-01-24 |
Mcneilab, Inc. |
Anticonvulsant sorbopyranose sulfamates
|
US5498629A
(en)
*
|
1993-12-23 |
1996-03-12 |
Ortho Pharmaceutical Corporation |
Anticonvulsant pseudofructopyranose sulfamates
|
AU695336B2
(en)
*
|
1993-12-23 |
1998-08-13 |
Ortho Pharmaceutical Corporation |
Anticonvulsant pseudofructopyranose sulfamates
|
US5998380A
(en)
*
|
1995-10-13 |
1999-12-07 |
New England Medical Center Hospitals, Inc. |
Treatment of migraine
|
KR970027051A
(ko)
*
|
1995-11-02 |
1997-06-24 |
조규향 |
카바모일기를 포함하는 신규한 설파메이트 화합물
|
AU3501697A
(en)
*
|
1996-06-28 |
1998-01-21 |
Ortho Pharmaceutical Corporation |
Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
|
US5753694A
(en)
*
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
|
AU730868B2
(en)
*
|
1996-06-28 |
2001-03-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating psoriasis
|
JP2000514425A
(ja)
*
|
1996-06-28 |
2000-10-31 |
オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド |
肥満の処置に有用な抗痙攣剤のスルファメート誘導体
|
US5753693A
(en)
*
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
|
ES2187795T3
(es)
*
|
1996-10-08 |
2003-06-16 |
Ortho Mcneil Pharm Inc |
Derivados de anticonvulsivos utiles en el tratamiento del dolor neuropatico.
|
JP3744089B2
(ja)
*
|
1996-12-02 |
2006-02-08 |
富士電機ホールディングス株式会社 |
マグネトロンスパッタ成膜装置および成膜方法
|
US5760006A
(en)
*
|
1997-06-23 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating psoriasis
|
US5760007A
(en)
*
|
1997-07-16 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating neuropathic pain
|
UA65607C2
(uk)
*
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
AU759756B2
(en)
*
|
1998-10-20 |
2003-05-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
|
ATE261724T1
(de)
*
|
1998-11-17 |
2004-04-15 |
Ortho Mcneil Pharm Inc |
Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
|
EP1143967B1
(en)
*
|
1999-01-19 |
2004-10-20 |
Ortho-Mcneil Pharmaceutical, Inc. |
Use of anticonvulsant derivatives for treating cluster headaches
|
AR022321A1
(es)
*
|
1999-01-21 |
2002-09-04 |
Ortho Mcneil Pharm Inc |
Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
|
CA2360677C
(en)
*
|
1999-02-01 |
2005-07-05 |
Scott P. Hoopes |
Anticonvulsant derivatives useful in treating bulimia nervosa
|
CA2361584C
(en)
*
|
1999-02-08 |
2005-06-14 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating autism
|
IL144943A0
(en)
*
|
1999-02-17 |
2002-06-30 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in treating essential tremor
|
ES2238999T3
(es)
*
|
1999-02-24 |
2005-09-16 |
University Of Cincinnati |
Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
|
MXPA01010221A
(es)
*
|
1999-04-08 |
2002-03-27 |
Johnson & Johnson |
Derivados anticonvulsivos utiles para disminuir la presion sanguinea.
|
JP2003530300A
(ja)
*
|
1999-04-08 |
2003-10-14 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
体重低下を維持することに有用な抗痙攣薬誘導体
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
MXPA01010218A
(es)
|
1999-04-08 |
2002-03-27 |
Johnson & Johnson |
Derivados anticonvulsivos utiles para disminuir lipidos.
|
MXPA01011014A
(es)
*
|
1999-04-30 |
2003-06-30 |
Johnson & Johnson |
Derivados anticonvulsivos utiles en el tratamiento de dependencia de cocaina.
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
MXPA01012187A
(es)
*
|
1999-05-28 |
2002-06-21 |
Jeffrey Berlant |
Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
|
US7553818B2
(en)
*
|
1999-06-14 |
2009-06-30 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US7674776B2
(en)
|
1999-06-14 |
2010-03-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US20080255093A1
(en)
*
|
1999-06-14 |
2008-10-16 |
Tam Peter Y |
Compositions and methods for treating obesity and related disorders
|
US7659256B2
(en)
*
|
1999-06-14 |
2010-02-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
ATE369126T1
(de)
|
1999-06-14 |
2007-08-15 |
Vivus Inc |
Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
|
US20080103179A1
(en)
*
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
SK286621B6
(sk)
*
|
1999-08-20 |
2009-02-05 |
Ortho-Mcneil Pharmaceutical, Inc. |
Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
|
US7335650B2
(en)
*
|
2000-01-14 |
2008-02-26 |
Sterix Limited |
Composition
|
SE0000601D0
(sv)
*
|
2000-02-24 |
2000-02-24 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
DE10027887A1
(de)
*
|
2000-05-31 |
2001-12-13 |
Jenapharm Gmbh |
Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
CN101404993A
(zh)
*
|
2000-07-07 |
2009-04-08 |
奥索-麦克尼尔药品公司 |
用于预防ii型糖尿病和x综合征的发展的抗惊厥剂衍生物
|
US6946243B2
(en)
|
2000-07-20 |
2005-09-20 |
Solvay Pharmaceuticals Gmbh |
Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
|
WO2002009694A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
BR0115055A
(pt)
|
2000-10-30 |
2003-12-30 |
Ortho Mcneil Pharm Inc |
Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
|
DOP2001000289A
(es)
|
2000-11-30 |
2003-02-15 |
Pfizer Prod Inc |
Combinación de agonistas de gaba e inhibidores de sorbitol- deshidrogenasa
|
CA2430010A1
(en)
*
|
2000-11-30 |
2002-06-06 |
University Of Florida |
Treatments for neurogenetic disorders, impulse control disorders, and wound healing
|
CA2430309A1
(en)
|
2000-11-30 |
2002-06-06 |
Pfizer Products Inc. |
Combination of gaba agonists and aldose reductase inhibitors
|
DE60219961T8
(de)
*
|
2001-02-02 |
2008-04-17 |
Ortho-Mcneil Pharmaceutical, Inc. |
Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
|
JP2004331502A
(ja)
*
|
2001-06-18 |
2004-11-25 |
Ortho Mcneil Pharmaceut Inc |
視神経細胞保護剤
|
US7041650B2
(en)
*
|
2001-07-09 |
2006-05-09 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivative salts
|
UA78211C2
(en)
*
|
2001-07-09 |
2007-03-15 |
Ortho Mcneil Pharm Inc |
Salts of fructopyranose derivatives as anticonvulsant
|
EP1450826A1
(en)
*
|
2001-11-06 |
2004-09-01 |
Ortho-Mcneil Pharmaceutical Corp. |
Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
|
US20090088443A1
(en)
*
|
2002-02-15 |
2009-04-02 |
Julius Remenar |
Novel crystalline forms of conazoles and methods of making and using the same
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US6559293B1
(en)
|
2002-02-15 |
2003-05-06 |
Transform Pharmaceuticals, Inc. |
Topiramate sodium trihydrate
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
UA81110C2
(en)
*
|
2002-02-26 |
2007-12-10 |
Ortho Mcneil Pharm Inc |
Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine
|
EP1494998A2
(en)
*
|
2002-03-01 |
2005-01-12 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US20040029941A1
(en)
*
|
2002-05-06 |
2004-02-12 |
Jennings Julianne E. |
Zonisamide use in obesity and eating disorders
|
US7060725B2
(en)
*
|
2002-05-13 |
2006-06-13 |
Janssen Pharmaceutica N.V. |
Substituted sulfamate anticonvulsant derivatives
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
EP1505967B1
(en)
*
|
2002-05-17 |
2016-07-13 |
Duke University |
Method for treating obesity
|
EP1364649A1
(en)
*
|
2002-05-23 |
2003-11-26 |
Cilag AG |
Adduct of topiramate and tramadol hydrochioride and uses thereof
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
CN100360117C
(zh)
*
|
2002-06-21 |
2008-01-09 |
转化医药公司 |
具有提高的溶出度的药物组合物
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
AU2003256848A1
(en)
*
|
2002-07-29 |
2004-02-16 |
Alza Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
WO2004024163A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Motac Neuroscience Limited |
Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
|
US20060069039A1
(en)
*
|
2002-09-17 |
2006-03-30 |
Alan Crossman |
Treatment of dyskinesia
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
US7196209B2
(en)
*
|
2002-10-31 |
2007-03-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Continuous process for the preparation of fructopyranose sulfamate derivatives
|
AU2003297639A1
(en)
*
|
2002-12-02 |
2004-06-23 |
University Of Florida |
Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
|
TW200427448A
(en)
*
|
2002-12-13 |
2004-12-16 |
Cilag Ag |
Controlled release preparations comprising tramadol and topiramate
|
US8183290B2
(en)
*
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
UA81657C2
(ru)
*
|
2003-03-04 |
2008-01-25 |
Орто-Макнейл Фармасьютикел, Инк. |
Способ получения противосудорожных производных топирамата
|
WO2004089965A2
(en)
*
|
2003-04-07 |
2004-10-21 |
Cipla Ltd |
Topiramate and processes for the preparation thereof
|
ES2303085T3
(es)
|
2003-04-29 |
2008-08-01 |
Orexigen Therapeutics, Inc. |
Composiciones que afectan a la perdida de peso.
|
WO2004108732A1
(en)
*
|
2003-05-12 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
|
CN1791430A
(zh)
*
|
2003-05-16 |
2006-06-21 |
辉瑞产品公司 |
非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合
|
WO2005016306A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Alza Corporation |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
AU2004268549A1
(en)
*
|
2003-08-22 |
2005-03-10 |
Alza Corporation |
Stepwise delivery of topiramate over prolonged period of time
|
EP1673064A1
(en)
*
|
2003-08-28 |
2006-06-28 |
Sandoz AG |
Pharmaceutical composition comprising anticonvulsant with taste mask coating
|
WO2005020959A2
(en)
*
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
CN1882533B
(zh)
|
2003-09-19 |
2010-06-09 |
詹森药业有限公司 |
4-((苯氧基烷基)硫基)-苯氧基乙酸及其类似物
|
MXPA06005462A
(es)
*
|
2003-11-14 |
2006-12-15 |
Johnson & Johnson |
Liberacion controlada de topiramato en formas de dosificacion liquida.
|
US20050176680A1
(en)
|
2003-12-11 |
2005-08-11 |
Sepracor, Inc. |
Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
EP1701708A2
(en)
*
|
2003-12-29 |
2006-09-20 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
AU2004312082A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation, Inc. |
Novel drug compositions and dosage forms
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
BRPI0506829A
(pt)
|
2004-01-13 |
2007-05-29 |
Univ Duke |
composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
|
EP1737466A1
(en)
*
|
2004-01-29 |
2007-01-03 |
Pfizer Products Inc. |
COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS
|
US20050203287A1
(en)
*
|
2004-03-11 |
2005-09-15 |
Chandrasekhar Batchu |
Process for the preparation of sulfamate derivatives
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
US7534780B2
(en)
*
|
2004-05-21 |
2009-05-19 |
Bayer Schering Pharma Aktiengesellschaft |
Estradiol prodrugs
|
US20050277625A1
(en)
*
|
2004-05-21 |
2005-12-15 |
Ralf Wyrwa |
Estriol and estetrol prodrugs
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
ATE341558T1
(de)
|
2004-08-19 |
2006-10-15 |
Helm Ag |
Verfahren zur herstellung von topiramate
|
DE602005008084D1
(de)
*
|
2004-08-24 |
2008-08-21 |
Janssen Pharmaceutica Nv |
Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
|
US20060276528A1
(en)
*
|
2004-08-24 |
2006-12-07 |
Abdel-Magid Ahmed F |
Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
|
KR20080012360A
(ko)
*
|
2005-05-20 |
2008-02-11 |
얀센 파마슈티카 엔.브이. |
설파미드 유도체의 제조 방법
|
WO2006125774A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Janssen Pharmaceutica N.V. |
Pediatric formulation of topiramate
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
JO3006B1
(ar)
*
|
2005-09-14 |
2016-09-05 |
Janssen Pharmaceutica Nv |
املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
|
BRPI0616263A2
(pt)
*
|
2005-09-23 |
2011-06-14 |
Janssen Pharmaceutica Nv |
moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
EP1931335B1
(en)
*
|
2005-09-23 |
2010-02-24 |
Janssen Pharmaceutica N.V. |
Hexahydro cyclooctyl pyrazole cannabinoid modulators
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
US20070123578A1
(en)
*
|
2005-09-23 |
2007-05-31 |
Fina Liotta |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
CA2624378A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Janssen Pharmaceutica N.V. |
Macroheterocylic compounds as kinase inhibitors
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
ES2761812T3
(es)
|
2005-11-22 |
2020-05-21 |
Nalpropion Pharmaceuticals Inc |
Composición y métodos de aumento de la sensibilidad a la insulina
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
US20070197488A1
(en)
*
|
2005-11-29 |
2007-08-23 |
Olaf Peters |
Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
|
US20070123500A1
(en)
*
|
2005-11-29 |
2007-05-31 |
Gerd Mueller |
Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
|
US20070135399A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Heteroaromatic sulphonamide prodrugs
|
US20070135375A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Sulfamoyl sulfonate prodrugs
|
US8716231B2
(en)
*
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US8492431B2
(en)
*
|
2005-12-19 |
2013-07-23 |
Janssen Pharmaceutica, N.V. |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
|
US20070155824A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US7526911B2
(en)
*
|
2006-02-03 |
2009-05-05 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
US7795294B2
(en)
*
|
2006-02-14 |
2010-09-14 |
Janssen Pharmaceutica N.V. |
Tetrahydro-2H-indazole pyrazole cannabinoid modulators
|
US20070191459A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
US20070191461A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
|
US20070191451A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
|
US20070191452A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
|
US20070191449A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
|
US20070191453A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
|
US20070191460A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
|
TW200738669A
(en)
*
|
2006-02-22 |
2007-10-16 |
Janssen Pharmaceutica Nv |
Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
|
WO2007099388A1
(en)
*
|
2006-03-01 |
2007-09-07 |
Glade Organics Private Limited |
An improved process for the manufacture of topiramate
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
EP1998776A4
(en)
*
|
2006-03-10 |
2009-07-08 |
Janssen Pharmaceutica Nv |
MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
WO2007112402A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Janssen Pharmaceutica N.V. |
Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
|
UY30288A1
(es)
*
|
2006-04-18 |
2007-08-31 |
Janssen Pharmaceutica Nv |
Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
EA200870556A1
(ru)
*
|
2006-05-19 |
2009-06-30 |
Янссен Фармацевтика Н.В. |
Комбинированная терапия в лечении эпилепсии и родственных расстройств
|
US20070293476A1
(en)
*
|
2006-05-19 |
2007-12-20 |
Smith-Swintosky Virginia L |
Co-therapy for the treatment of epilepsy and related disorders
|
WO2008010231A2
(en)
*
|
2006-05-26 |
2008-01-24 |
Alembic Limited |
A process for the purification of topiramate
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
PT2061458E
(pt)
*
|
2006-09-15 |
2015-03-11 |
Univ Minnesota |
Composições de topiramato e métodos para a sua utilização
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
KR20090090316A
(ko)
*
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
JP2010509367A
(ja)
|
2006-11-09 |
2010-03-25 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
積層製剤
|
DE07870164T1
(de)
|
2006-11-17 |
2009-02-19 |
Supernus Pharmaceuticals, Inc. |
Verzögert freigesetzte formulierungen aus topiramat
|
EP2061431B1
(en)
|
2006-12-04 |
2013-04-24 |
Supernus Pharmaceuticals, Inc. |
Enhanced immediate release formulations of topiramate
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
US20090076128A1
(en)
*
|
2007-09-15 |
2009-03-19 |
Protia Llc |
Deuterium-enriched topiramate
|
AR070949A1
(es)
*
|
2007-10-19 |
2010-05-19 |
Solvay Pharm Gmbh |
Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
|
WO2009105140A2
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
AU2008353491A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Janssen Pharmaceutica N.V. |
Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of N- ( ( (2S) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide
|
WO2009158114A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
US20090304789A1
(en)
*
|
2008-06-09 |
2009-12-10 |
Thomas Najarian |
Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
|
US8580298B2
(en)
*
|
2008-06-09 |
2013-11-12 |
Vivus, Inc. |
Low dose topiramate/phentermine composition and methods of use thereof
|
US20090318520A1
(en)
|
2008-06-20 |
2009-12-24 |
Afecta Pharmaceuticals Drive |
Use of isoindoles for the treatment of neurobehavioral disorders
|
WO2010008776A2
(en)
|
2008-06-23 |
2010-01-21 |
Janssen Pharmaceutica Nv |
Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
EP2429292B1
(en)
*
|
2009-05-08 |
2019-04-03 |
Georgia State University Research Foundation |
Compounds and compositions comprising cdk inhibitors and their use in the treatment of cancer
|
JP6196041B2
(ja)
|
2010-01-11 |
2017-09-13 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
大うつ病を有する患者において減量療法を提供する方法
|
EP2367836B8
(en)
|
2010-02-05 |
2015-09-02 |
Scinopharm Taiwan Ltd. |
Process for the preparation and purification of topiramate
|
BR112014030282A2
(pt)
|
2012-06-06 |
2017-06-27 |
Orexigen Therapeutics Inc |
métodos de tratamento de excesso de peso e obesidade
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
MX365914B
(es)
|
2013-03-15 |
2019-06-20 |
Aprecia Pharmaceuticals LLC |
Forma de dosificación de topiramato dispersable rápidamente.
|
CN103910770B
(zh)
*
|
2014-03-14 |
2017-01-04 |
天津南开允公医药科技有限公司 |
一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
|
EP3883546A1
(en)
|
2018-11-21 |
2021-09-29 |
Rosemont Pharmaceuticals Ltd |
Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
|